Biovica signs second agreement with leading US healthcare provider

2023-09-25 08:00

Biovica, active in cancer monitoring, today announces that the company has signed its second US hospital agreement for DiviTum® TKa with the largest healthcare provider in Missouri, a state covering about two percent of the US population.

The healthcare provider operates 18 hospitals of which one is a National Cancer Institute (NCI) Comprehensive Cancer Center and has been a partner to Biovica during the clinical development of DiviTum® TKa.

“We are immensely grateful for having had such an outstanding partner throughout our clinical development process and look forward to further deepening our partnership. The agreement represents the growing interest in and tremendous potential impact of DiviTum® TKa in the US market,” said Warren Cresswell, President of the Americas.


Numbers of patients in studies




Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program